Aleva Neurotherapeutics is a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor.
Aleva Neurotherapeutics develops the next generation of implantable Directional Deep Brain Stimulation systems based on MEMS technology.
Aleva was founded in 2008 as a spin-off of the Swiss Federal Institute of Technology in Lausanne, Switzerland. The companys founders are André Mercanzini, Jean-Pierre Rosat, Claudio Pollo, Philipe Renaud and Paul Pyzowski.
Aleva's unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. The first application is in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.
Aleva’s revolutionary DBS system incorporates directional electrode technology and is designed to be more precise and efficient, with optimized stimulation that will potentially reduce side effects.
Aleva is the only emerging technology company to be awarded the CE-Mark for Deep Brain Stimulation. The Company will initiate direct sales through a post-market clinical follow-up study in select European neurological clinics.
Aleva is backed by renowned institutional investors, among them Forrestal Capital, Kinled Holding, BioMedPartners (through its BioMedInvest-II LP Fund), BB Biotech Ventures LP, Kreaxi and Initiative Capital Romandie, as well as from select private investors. The company raised $8M in a Series E financing on Dec 16, 2019. This new round brings Aleva's total funding to $57.1M to date.